Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
681-700 of 1,307 trials

Benzodiazepine Dependence: Stabilizing Treatment Study

We are examining how a stable dose of benzodiazepines affects people with benzodiazepine dependence who are also receiving opioid therapy. The study looks at impacts on drug use, mental and physical health, and overall quality of life.

Benzodiazepine Dependence1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePsychiatry

Brivaracetam for Childhood Absence Epilepsy

We are studying whether brivaracetam is effective and safe for children and young adults aged 2 to 25 with childhood or juvenile absence epilepsy. This trial aims to provide insights into its use as a standalone treatment.

Childhood Absence Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Acute Myeloid Leukemia: Gemtuzumab Ozogamicin with Chemotherapy

We are studying whether adding gemtuzumab ozogamicin to standard chemotherapy helps reduce minimal residual disease in adults with newly diagnosed acute myeloid leukemia. This research aims to improve treatment outcomes and overall survival.

Favorable-Intermediate-Risk Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Myopia in Children: Atropine Eyedrops Study

We are testing two concentrations of atropine eyedrops to see if they can slow the progression of myopia in children and teens aged 3 to under 18. The study will also look at safety and how vision affects daily life.

Myopia>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology

Septic Shock: Levetiracetam Treatment Study

We are studying whether early treatment with levetiracetam can help patients with septic shock stay awake and alert. The trial also examines its effects on survival and overall quality of life.

Septic Shock>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicineNeurologyPulmonology

Interstitial Lung Disease: Rituximab and Mycophenolate Combination

We are studying a combination of rituximab and mycophenolate mofetil for patients with interstitial lung disease related to systemic sclerosis. The goal is to see if this treatment improves lung function and overall health compared to a placebo.

Lung Involvement in Systemic Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesPulmonologyRheumatology

High-Risk Myelodysplastic Syndromes: Stem Cell Transplantation Study

We are evaluating a new treatment approach that combines hypomethylating therapy with stem cell transplantation for patients with high-risk myelodysplastic syndromes. The study aims to assess the feasibility and safety of this combined treatment.

Myelodysplastic SyndromeConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology

Mucositis Prevention: Dexpanthenol Mouth Rinse

We are studying whether a new mouth rinse can help reduce mouth sores in patients receiving radiation therapy. The trial compares this rinse to a placebo to see if it improves comfort and quality of life.

Radiation-Induced Oral Mucositis>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatologyOncologyOtolaryngology

Inhaled Therapy for High-Risk Thoracic Surgery Patients

We are studying whether using a bronchodilator before and after surgery helps reduce lung complications in patients at high risk. This trial will also look at other health outcomes and quality of life after surgery.

Postoperative Pulmonary ComplicationsConfirmation phase (III)Standard MedicinesPartially RemotePulmonology

High-Risk Medulloblastoma: New Treatment Approaches

We are exploring whether new radiotherapy and chemotherapy methods improve outcomes for children and adults with high-risk medulloblastoma. The study also looks at the long-term effects of these treatments on patients' health and quality of life.

Medulloblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Kidney Transplant Rejection: INTERCEPT Study

We are studying whether adding TCZ to standard treatment helps kidney transplant recipients with chronic rejection maintain better kidney function. The trial also looks at the safety of this treatment and its effects on overall health.

Chronic Active Antibody-Mediated Rejection>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Glioma Treatment Study: Temozolomide and Lomustine

We are testing a combination of chemotherapy and radiotherapy for patients with newly diagnosed grade 2 or 3 glioma. The goal is to see if this approach improves survival compared to standard treatments.

Newly Diagnosed Glioma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Acute Heart Failure: Diuretic Treatment Study

We are investigating the best diuretic strategies for patients with acute heart failure and volume overload. This study aims to improve treatment options for those at risk of diuretic resistance.

Acute Heart Failure>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

Acute Myeloid Leukemia: Venetoclax and Azacitidine Treatment

We are studying whether a combination of venetoclax and azacitidine can help clear residual disease in AML patients before a stem cell transplant. This trial also looks at the safety and effectiveness of this treatment approach.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Soft Tissue Sarcoma: Oral Cyclophosphamide vs Doxorubicin

We are comparing the effectiveness of oral cyclophosphamide and doxorubicin in treating elderly patients with advanced soft tissue sarcoma. The goal is to find out which treatment may lead to better outcomes and fewer side effects.

Soft Tissue SarcomaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Chronic Migraine: Eptinezumab for Teens

We are studying whether eptinezumab can help reduce the number of migraine days in adolescents aged 12 to 17 with chronic migraine. This trial compares the medication to a placebo to assess its effectiveness.

Migraine3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

HIV Prevention: Long-Acting Injectable Cabotegravir vs. Daily Oral Medication

We are studying whether a long-acting injectable form of cabotegravir is more effective than daily oral medication for preventing HIV in men who have sex with men. This trial aims to understand how well each option works over time and their impact on participants' health and behaviors.

HIV Prevention>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Follicular Lymphoma: Tazemetostat with Lenalidomide and Rituximab

We are studying the safety and effectiveness of tazemetostat combined with lenalidomide and rituximab in adults with relapsed or refractory follicular lymphoma. This trial compares the new treatment to a placebo to see how well it works.

Relapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesHematologyOncology

Mpox Booster Vaccine: Fractional vs. Full Dose

We are studying whether a smaller booster dose of the MVA-BN vaccine is as effective as the standard dose in adults. This trial will also look at the safety and immune response of both doses.

Mpox (Monkeypox)3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Membranous Nephropathy: Personalized Rituximab Treatment Study

We are exploring whether an AI-driven personalized treatment plan for membranous nephropathy is more effective than standard rituximab treatment. This study aims to improve patient outcomes and remission rates.

Acute GlomerulonephritisMembranous Nephropathy6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesNephrology